Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher S Hourigan

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Blood|May 8, 2025
From prognostication to precision in acute myeloid leukemiaChristopher S Hourigan
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2014
Next generation MRDChristopher S Hourigan
Blood|September 9, 2017
Haplo, we have a problemChristopher S Hourigan
Current Drug Targets|March 8, 2017
Editorial: Targets for Immunotherapy in Acute LeukemiaChristopher S Hourigan
Hematology. American Society of Hematology. Education Program|December 9, 2022
Achieving MRD negativity in AML: how important is this and how do we get there?Christopher S Hourigan
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|October 11, 2005
Registering organ donor preferences - a third way?Christopher S Hourigan
BMJ (Clinical Research Ed.)|November 5, 2005
Are medical schools fit for graduates?Christopher S Hourigan
Seminars in Hematology|April 16, 2026
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?Christopher S Hourigan
Blood|July 11, 2024
How complete must an AML remission be?Christopher S Hourigan
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid LeukemiaGege Gui, Christopher S Hourigan
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Blood|May 8, 2025
From prognostication to precision in acute myeloid leukemiaChristopher S Hourigan
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 13, 2014
Next generation MRDChristopher S Hourigan
Blood|September 9, 2017
Haplo, we have a problemChristopher S Hourigan
Current Drug Targets|March 8, 2017
Editorial: Targets for Immunotherapy in Acute LeukemiaChristopher S Hourigan
Hematology. American Society of Hematology. Education Program|December 9, 2022
Achieving MRD negativity in AML: how important is this and how do we get there?Christopher S Hourigan
The British Journal of General Practice : the Journal of the Royal College of General Practitioners|October 11, 2005
Registering organ donor preferences - a third way?Christopher S Hourigan
BMJ (Clinical Research Ed.)|November 5, 2005
Are medical schools fit for graduates?Christopher S Hourigan
Seminars in Hematology|April 16, 2026
Role of MRD testing in acute myeloid leukemias. What is the status and how to get there?Christopher S Hourigan
Blood|July 11, 2024
How complete must an AML remission be?Christopher S Hourigan
Cancer Journal (Sudbury, Mass.)|January 24, 2022
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid LeukemiaGege Gui, Christopher S Hourigan
Pageof 15